TintoreMVidal-JordanaASastre-GarrigaJ. Treatment of multiple sclerosis – Success from bench to bedside. Nat Rev Neurol2019; 15(1): 53–58.
2.
Multiple sclerosis under the spotlight. Lancet Neurol2021; 20: 497.
3.
TrojanoMIaffaldanoP. Assessing long-term effectiveness of MS treatment – A matter of debate. Nat Rev Neurol2021; 17(4): 197–198.
4.
RollotFCaseyRLerayE, et al. Cumulative effects of therapies on disability in relapsing multiple sclerosis. Mult Scler. Epub ahead of print 6 January 2021. DOI: 10.1177/1352458520980366.
5.
KavaliunasAManouchehriniaAStawiarzL, et al. Importance of early treatment initiation in the clinical course of multiple sclerosis. Mult Scler2017; 23(9): 1233–1240.
6.
IaffaldanoPLucisanoGButzkuevenH, et al. Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network. Mult Scler2021; 27(10): 1543–1555.
7.
KalincikTDioufISharminS, et al. Effect of disease-modifying therapy on disability in relapsing-remitting multiple sclerosis over 15 years. Neurol2021; 96: e783–e797.
8.
BrownJWLColesAHorakovaD, et al. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA2019; 321: 175–187.
9.
StankiewiczJMWeinerHL. An argument for broad use of high efficacy treatments in early multiple sclerosis. Neurol Neuroimmunol Neuroinflamm2020; 7(1): 0636.
10.
HardingKWilliamsOWillisM, et al. Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurol2019; 76: 536–541.
11.
HeAMerkelBBrownJWL, et al. Timing of high-efficacy therapy for multiple sclerosis: A retrospective observational cohort study. Lancet Neurol2020; 19(4): 307–316.
12.
BuronMDChalmerTASellebjergF, et al. Initial high-efficacy disease-modifying therapy in multiple sclerosis. A nationwide cohort study. Neurol2020; 95: e1041–e1051.
13.
IaffaldanoPLucisanoGCaputoF, et al. Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. Ther Adv Neurol Dis2021; 14: 1–10.
